University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with non-small cell lung cancer across Australia, the United States and Europe.
Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...
Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...
Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...
News-Medical.Net on MSN
Innovative CRISPR strategy resensitizes lung cancer to treatment
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...
Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...
AI-driven early detection, personalized therapies, and immune-rejuvenating T-cell engineering promise transformative, durable cancer treatments, potentially reshaping aging and long-term survival.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback